Welcome, Guest. Please login or register.
October 04, 2023, 01:43:15 pm

Login with username, password and session length

  • Total Posts: 55101
  • Total Topics: 4848
  • Online Today: 106
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 52
Total: 52


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Albumin and Liver Stiffness Signal Risk of Liver Cancer After Hep C Cure  (Read 4250 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
To identify who among those receiving direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) is at elevated risk for liver cancer, look to albumin and liver stiffness levels during the period following treatment, Healio reports.

That’s according to a new study led by Mònica Pons, MD, of the Vall d’Hebron Research Institute in Barcelona, and published in the Journal of Hepatology.

The study analyzed data on 1,563 people who received DAA treatment for HCV, 572 of whom had compensated advanced chronic liver disease. A total of 97.1% achieved a sustained virologic response 12 weeks after completing therapy (SVR12), considered a cure.



© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.